2 months Regeneron to Report Q3 Earnings: What’s in the Offing? Zacks
Investors’ focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports third-quarter 2024 results.
Biotech · Earnings · Pharmaceuticals · Regeneron Pharma (REGN)
X